Description
In this video, Dr. Ronald Goldenberg, an endocrinologist at LMC Diabetes and Endocrinology, discusses the evolving landscape of first-line therapy for type 2 diabetes. He reviews the historical role of metformin, the impact of landmark trials such as the UK Prospective Diabetes Study and explores the potential benefits of newer agents like SGLT2 inhibitors and GLP-1 receptor agonists, emphasizing individualized treatment approaches based on patient profiles and comorbidities.